21 results on '"Canto, M.I."'
Search Results
2. Timeline of Development of Pancreatic Cancer and Implications for Successful Early Detection in High-Risk Individuals
- Author
-
Overbeek, K.A., Goggins, M.G., Dbouk, M., Levink, I.J.M., Koopmann, B.D.M., Chuidian, M., Konings, I.C.A.W., Paiella, S., Earl, J., Fockens, P., Gress, T.M., Ausems, M.G.E.M., Poley, J.W., Thosani, N.C., Half, E., Lachter, J., Stoffel, E.M., Kwon, R.S., Stoita, A., Kastrinos, F., Lucas, A.L., Syngal, S., Brand, R.E., Chak, A., Carrato, A., Vleggaar, F.P., Bartsch, D.K., Hooft, J.E. van, Cahen, D.L., Canto, M.I., Bruno, M.J., Int Canc Pancreas Screening Consor, Gastroenterology and hepatology, Gastroenterology and Hepatology, CCA - Cancer Treatment and Quality of Life, AGEM - Amsterdam Gastroenterology Endocrinology Metabolism, and Gastroenterology & Hepatology
- Subjects
medicine.medical_specialty ,Surveillance ,Hepatology ,Intraductal papillary mucinous neoplasm ,medicine.diagnostic_test ,business.industry ,Familial Pancreatic Cancer ,Gastroenterology ,Pancreatic Intraepithelial Neoplasia ,medicine.disease ,Lesion ,Pancreatic Cancer ,medicine.anatomical_structure ,Fine-needle aspiration ,SDG 3 - Good Health and Well-being ,Dysplasia ,Interquartile range ,Pancreatic cancer ,medicine ,Screening ,Radiology ,medicine.symptom ,Pancreas ,business - Abstract
Background & Aims: To successfully implement imaging-based pancreatic cancer (PC) surveillance, understanding the timeline and morphologic features of neoplastic progression is key. We aimed to investigate the progression to neoplasia from serial prediagnostic pancreatic imaging tests in high-risk individuals and identify factors associated with successful early detection. Methods: We retrospectively examined the development of pancreatic abnormalities in high-risk individuals who were diagnosed with PC or underwent pancreatic surgery, or both, in 16 international surveillance programs. Results: Of 2552 high-risk individuals under surveillance, 28 (1%) developed neoplastic progression to PC or high-grade dysplasia during a median follow-up of 29 months after baseline (interquartile range [IQR], 40 months). Of these, 13 of 28 (46%) presented with a new lesion (median size, 15 mm; range 7–57 mm), a median of 11 months (IQR, 8; range 3–17 months) after a prior examination, by which time 10 of 13 (77%) had progressed beyond the pancreas. The remaining 15 of 28 (54%) had neoplastic progression in a previously detected lesion (12 originally cystic, 2 indeterminate, 1 solid), and 11 (73%) had PC progressed beyond the pancreas. The 12 patients with cysts had been monitored for 21 months (IQR, 15 months) and had a median growth of 5 mm/y (IQR, 8 mm/y). Successful early detection (as high-grade dysplasia or PC confined to the pancreas) was associated with resection of cystic lesions (vs solid or indeterminate lesions (odds ratio, 5.388; 95% confidence interval, 1.525–19.029) and small lesions (odds ratio, 0.890/mm; 95% confidence interval 0.812–0.976/mm). Conclusions: In nearly half of high-risk individuals developing high-grade dysplasia or PC, no prior lesions are detected by imaging, yet they present at an advanced stage. Progression can occur before the next scheduled annual examination. More sensitive diagnostic tools or a different management strategy for rapidly growing cysts are needed.
- Published
- 2022
- Full Text
- View/download PDF
3. Management of patients with increased risk for familial pancreatic cancer: updated recommendations from the International Cancer of the Pancreas Screening (CAPS) Consortium
- Author
-
Goggins, M., Overbeek, K.A., Brand, R., Syngal, S., Chiaro, M. del, Bartsch, D.K., Bassi, C., Carrato, A., Farrell, J., Fishman, E.K., Fockens, P., Gress, T.M., Hooft, J.E. van, Hruban, R.H., Kastrinos, F., Klein, A., Lennon, A.M., Lucas, A., Park, W., Rustgi, A., Simeone, D., Stoffel, E., Vasen, H.F.A., Cahen, D.L., Canto, M.I., Bruno, M., Arcidiacono, P.G., Ashida, R., Ausems, M., Besselink, M., Biermann, K., Bonsing, B., Brentnall, T., Chak, A., Early, D., Fernandez-Del Castillo, C., Frucht, H., Furukawa, T., Gallinger, S., Geurts, J., Koerkamp, B.G., Hammel, P., Hes, F., Iglesias-Garcia, J., Kamel, I., Kitano, M., Kloppel, G., Krak, N., Kurtz, R., Kwon, R., Lachter, J., Lee, J., Levy, M., Malleo, G., Meguid, C., Maitra, A., Margolis, D., Offerhaus, J., Olson, S., Paiella, S., Petersen, G., Poley, J.W., Real, F.X., Saltzman, J., Schulick, R., Stoita, A., Takaori, K., Tanaka, M., Tamm, E., Topazian, M., Vazquez-Sequeiros, E., Vleggaar, F., Cappel, W.D.T.N., Yeo, C., Wasser, M., Wagner, A., Wallace, M., Wolfgang, C., Wood, L., Int Canc Pancreas Screening, Goggins, M., Overbeek, K. A., Brand, R., Syngal, S., Del Chiaro, M., Bartsch, D. K., Bassi, C., Carrato, A., Farrell, J., Fishman, E. K., Fockens, P., Gress, T. M., Van Hooft, J. E., Hruban, R. H., Kastrinos, F., Klein, A., Lennon, A. M., Lucas, A., Park, W., Rustgi, A., Simeone, D., Stoffel, E., Vasen, H. F. A., Cahen, D. L., Canto, M. I., Bruno, M, Arcidiacono, P. G., Gastroenterology & Hepatology, Clinical sciences, Medical Genetics, Gastroenterology and Hepatology, AGEM - Digestive immunity, AGEM - Re-generation and cancer of the digestive system, and CCA - Cancer Treatment and Quality of Life
- Subjects
Endoscopic ultrasound ,medicine.medical_specialty ,Biomedical Research ,MEDLINE ,pancreatic ductal adenocarcinoma ,familial pancreatic cancer ,Biomedical Research/methods ,Article ,Germline mutation ,Mass Screening/methods ,SDG 3 - Good Health and Well-being ,Risk Factors ,Pancreatic cancer ,medicine ,Humans ,Mass Screening ,Pancreatic Neoplasms/diagnosis ,Age Factor ,Genetic Predisposition to Disease ,Family history ,Intensive care medicine ,early detection ,Early Detection of Cancer ,Germ-Line Mutation ,Medicine(all) ,Hereditary pancreatitis ,medicine.diagnostic_test ,business.industry ,Carcinoma ,Age Factors ,Gastroenterology ,Pancreatic Neoplasm ,Cancer ,medicine.disease ,Carcinoma/diagnosis ,Population Surveillance/methods ,Pancreatic Neoplasms ,medicine.anatomical_structure ,Population Surveillance ,surveillance ,Early Detection of Cancer/methods ,business ,Pancreas ,genetic predisposition ,Human - Abstract
Background and aimThe International Cancer of the Pancreas Screening Consortium met in 2018 to update its consensus recommendations for the management of individuals with increased risk of pancreatic cancer based on family history or germline mutation status (high-risk individuals).MethodsA modified Delphi approach was employed to reach consensus among a multidisciplinary group of experts who voted on consensus statements. Consensus was considered reached if ≥75% agreed or disagreed.ResultsConsensus was reached on 55 statements. The main goals of surveillance (to identify high-grade dysplastic precursor lesions and T1N0M0 pancreatic cancer) remained unchanged. Experts agreed that for those with familial risk, surveillance should start no earlier than age 50 or 10 years earlier than the youngest relative with pancreatic cancer, but were split on whether to start at age 50 or 55. Germline ATM mutation carriers with one affected first-degree relative are now considered eligible for surveillance. Experts agreed that preferred surveillance tests are endoscopic ultrasound and MRI/magnetic retrograde cholangiopancreatography, but no consensus was reached on how to alternate these modalities. Annual surveillance is recommended in the absence of concerning lesions. Main areas of disagreement included if and how surveillance should be performed for hereditary pancreatitis, and the management of indeterminate lesions.ConclusionsPancreatic surveillance is recommended for selected high-risk individuals to detect early pancreatic cancer and its high-grade precursors, but should be performed in a research setting by multidisciplinary teams in centres with appropriate expertise. Until more evidence supporting these recommendations is available, the benefits, risks and costs of surveillance of pancreatic surveillance need additional evaluation.
- Published
- 2020
4. Efficacy of Per-oral Methylene Blue Formulation for Screening Colonoscopy
- Author
-
Repici, A., Wallace, M.B., East, J.E., Sharma, P., Ramirez, F.C., Bruining, D.H., Young, M., Gatof, D., Canto, M.I., Marcon, N., Cannizzaro, R., Kiesslich, R., Rutter, M., Dekker, E., Siersema, P.D., Spaander, M., Kupcinskas, L., Jonaitis, L., Bisschops, R., Radaelli, F., Bhandari, P., Wilson, A., Early, D., Gupta, N., Vieth, M., Lauwers, G.Y., Rossini, M., Hassan, C., Repici, A., Wallace, M.B., East, J.E., Sharma, P., Ramirez, F.C., Bruining, D.H., Young, M., Gatof, D., Canto, M.I., Marcon, N., Cannizzaro, R., Kiesslich, R., Rutter, M., Dekker, E., Siersema, P.D., Spaander, M., Kupcinskas, L., Jonaitis, L., Bisschops, R., Radaelli, F., Bhandari, P., Wilson, A., Early, D., Gupta, N., Vieth, M., Lauwers, G.Y., Rossini, M., and Hassan, C.
- Abstract
Contains fulltext : 205156.pdf (publisher's version ) (Closed access), BACKGROUND & AIMS: Topically applied methylene blue dye chromoendoscopy is effective in improving detection of colorectal neoplasia. When combined with a pH- and time-dependent multimatrix structure, a per-oral methylene blue formulation (MB-MMX) can be delivered directly to the colorectal mucosa. METHODS: We performed a phase 3 study of 1205 patients scheduled for colorectal cancer screening or surveillance colonoscopies (50-75 years old) at 20 sites in Europe and the United States, from December 2013 through October 2016. Patients were randomly assigned to groups given 200 mg MB-MMX, placebo, or 100 mg MB-MMX (ratio of 2:2:1). The 100-mg MB-MMX group was included for masking purposes. MB-MMX and placebo tablets were administered with a 4-L polyethylene glycol-based bowel preparation. The patients then underwent colonoscopy by an experienced endoscopist with centralized double-reading. The primary endpoint was the proportion of patients with 1 adenoma or carcinoma (adenoma detection rate [ADR]). We calculated odds ratios (ORs) and 95% confidence intervals (CIs) for differences in detection between the 200-mg MB-MMX and placebo groups. False-positive (resection rate for non-neoplastic polyps) and adverse events were assessed as secondary endpoints. RESULTS: The ADR was higher for the MB-MMX group (273 of 485 patients, 56.29%) than the placebo group (229 of 479 patients, 47.81%) (OR 1.46; 95% CI 1.09-1.96). The proportion of patients with nonpolypoid lesions was higher in the MB-MMX group (213 of 485 patients, 43.92%) than the placebo group (168 of 479 patients, 35.07%) (OR 1.66; 95% CI 1.21-2.26). The proportion of patients with adenomas =5 mm was higher in the MB-MMX group (180 of 485 patients, 37.11%) than the placebo group (148 of 479 patients, 30.90%) (OR 1.36; 95% CI 1.01-1.83), but there was no difference between groups in detection of polypoid or larger lesions. The false-positive rate did not differ significantly between groups (83 [23.31%] of 356 patients
- Published
- 2019
5. Surveillance for pancreatic cancer in high-risk individuals
- Author
-
Konings, I., Canto, M.I. (Marcia Irene), Almario, J.A., Harinck, E., Saxena, P, Lucas, A.L., Kastrinos, E., Whitcomb, D.C., Brand, R.E., Lachter, J., Malleo, G, Paiella, S, Syngal, S. (Sapna), Saltzman, J.R., Stoffel, E.M. (Elena), Hooft, J.E. (Jeanin) van, Hruban, R.H. (Ralph), Poley, J.-W. (Jan-Werner), Fockens, P. (Paul), Goggins, M.G., Bruno, M.J. (Marco), Konings, I., Canto, M.I. (Marcia Irene), Almario, J.A., Harinck, E., Saxena, P, Lucas, A.L., Kastrinos, E., Whitcomb, D.C., Brand, R.E., Lachter, J., Malleo, G, Paiella, S, Syngal, S. (Sapna), Saltzman, J.R., Stoffel, E.M. (Elena), Hooft, J.E. (Jeanin) van, Hruban, R.H. (Ralph), Poley, J.-W. (Jan-Werner), Fockens, P. (Paul), Goggins, M.G., and Bruno, M.J. (Marco)
- Abstract
Background: Surveillance of individuals at high risk of pancreatic ductal adenocarcinoma (PDAC) and its precursors might lead to better outcomes. The aim of this study was to determine the prevalence and outcomes of PDAC and high-risk neoplastic precursor lesions among such patients participating in surveillance programmes. Methods: A multicentre study was conducted through the International CAncer of the Pancreas Screening (CAPS) Consortium Registry to identify high-risk individuals who had undergone pancreatic resection or progressed to advanced PDAC while under surveillance. High-risk neoplastic precursor lesions were defined as: pancreatic intraepithelial neoplasia (PanIN) 3, intraductal papillary mucinous neoplasia (IPMN) with high-grade dysplasia, and pancreatic neuroendocrine tumours at least 2 cm in diameter. Results: Of 76 high-risk individuals identified in 11 surveillance programmes, 71 had undergone surgery and five had been diagnosed with inoperable PDAC. Of the 71 patients who underwent resection, 32 (45 per cent) had PDAC or a high-risk precursor (19 PDAC, 4 main-duct IPMN, 4 branch-duct IPMN, 5 PanIN-3); the other 39 patients had lesions thought to be associated with a lower risk of neoplastic progression. Age at least 65 years, female sex, carriage of a gene mutation and location of a lesion in the head/uncinate region were associated with high-risk precursor lesions or PDAC. The survival of high-risk individuals with low-risk neoplastic lesions did not differ from that in those with high-risk precursor lesions. Survival was worse among patients with PDAC. There was no surgery-related mortality. Conclusion: A high proportion of high-risk individuals who had surgical resection for screening- or surveillance-detected pancreatic lesions had a high-risk neoplastic precursor lesion or PDAC a
- Published
- 2019
- Full Text
- View/download PDF
6. Supplementary Material for: Elevated microRNA miR-21 Levels in Pancreatic Cyst Fluid Are Predictive of Mucinous Precursor Lesions of Ductal Adenocarcinoma
- Author
-
Ryu, J.K., Matthaei, H., Dal Molin, M., Hong, S.-M., Canto, M.I., Schulick, R.D., Wolfgang, C., Goggins, M.G., Hruban, R.H., Cope, L., and Maitra, A.
- Abstract
Background: Biomarkers for the diagnostic classification of pancreatic cysts are urgently needed. Deregulated microRNA (miRNAs) expression is widespread in pancreatic cancer. We assessed whether aberrant miRNAs in pancreatic cyst fluid could be used as potential biomarkers for cystic precursor lesions of pancreatic cancer. Methods: Cyst fluid specimens were prospectively collected from 40 surgically resected pancreatic cysts, and small RNAs were extracted. The ‘mucinous’ cohort included 14 intraductal papillary mucinous neoplasms (including 3 with an associated adenocarcinoma) and 10 mucinous cystic neoplasms; the ‘nonmucinous’ cohort included 11 serous cystadenomas and 5 other benign cysts. Quantitative reverse transcription PCR was performed for five miRNAs (miR-21, miR-155, miR-221, miR-17-3p, miR-191), which were previously reported as overexpressed in pancreatic adenocarcinomas. Results: Significantly higher expression of miR-21, miR-221, and miR-17-3p was observed in the mucinous versus nonmucinous cysts (p < 0.01), with the mean relative fold differences being 7.0-, 7.9-, and 5.4-fold, respectively. Receiver operating characteristic curves demonstrated the highest median area under the curve for miR-21, with a median specificity of 76%, at a sensitivity of 80%. Conclusion: This pilot study demonstrates that profiling miRNAs in pancreatic cyst fluid samples is feasible and can yield potential biomarkers for the classification of cystic lesions of the pancreas.
- Published
- 2017
- Full Text
- View/download PDF
7. Treatment of Barrett's esophagus with a novel focal cryoablation device: a safety and feasibility study
- Author
-
Scholvinck, D.W., Kunzli, H.T., Kestens, C., Siersema, P.D., Vleggaar, F.P., Canto, M.I., Cosby, H., Abrams, J.A., Lightdale, C.J., Tejeda-Ramirez, E., DeMeester, S.R., Greene, C.L., Jobe, B.A., Peters, J., Bergman, J.J., Weusten, B.L., Scholvinck, D.W., Kunzli, H.T., Kestens, C., Siersema, P.D., Vleggaar, F.P., Canto, M.I., Cosby, H., Abrams, J.A., Lightdale, C.J., Tejeda-Ramirez, E., DeMeester, S.R., Greene, C.L., Jobe, B.A., Peters, J., Bergman, J.J., and Weusten, B.L.
- Abstract
Item does not contain fulltext, BACKGROUND AND AIMS: Currently, eradication of Barrett's epithelium is preferably achieved using radiofrequency ablation (RFA) or spray cryoablation (SCA). However, both modalities suffer from drawbacks such as the need for sizing, multiple deployment steps, large controller units (RFA), imprecise dosing and need for gas-venting (SCA). The new Cryoballoon Focal Ablation System (CbFAS) may address these limitations. This study assessed the safety, feasibility, and dose response of the CbFAS in patients with flat Barrett's epithelium with or without dysplasia. PATIENTS AND METHODS: In this multicenter, prospective non-randomized trial, 39 patients were each treated with one or two ablations of 6, 8, or 10 seconds. Symptoms were assessed immediately and 2 days post-cryoablation. Follow-up endoscopy was performed 6 - 8 weeks post-procedure to assess response. Outcome parameters were incidence of adverse events, pain, esophageal stricture formation, and ablation response by cryogen dose. RESULTS: Of 62 ablations, 56 (10 with 6 seconds, 28 with 8 seconds, 18 with 10 seconds) were successfully performed. Six ablations failed because of device malfunction (n = 3) and procedural or anatomic issues (n = 3). Median procedure time was 7 minutes (interquartile range [IQR] 4 - 10). No major adverse events occurred; six patients experienced a minor mucosal laceration requiring no intervention. Mild pain was reported by 27 % of patients immediately after cryoablation and by 14 % after 2 days. No strictures were evident at follow-up. Full squamous regeneration was seen in 47 treated areas (6 [60 %] of the 6-second areas; 23 [82 %] of the 8-second areas; 18 [100 %] of 10-second areas). CONCLUSIONS: Focal cryoablation of Barrett's epithelium with the CbFAS is feasible and safe, resulting in squamous regeneration in the majority of patients.
- Published
- 2015
8. International Cancer of the Pancreas Screening (CAPS) Consortium summit on the management of patients with increased risk for familial pancreatic cancer.
- Author
-
Canto, M.I., Harinck, F., Hruban, R.H., Offerhaus, G.J.A., Poley, J.W., Kamel, I., Nio, Y., Schulick, R.S., Bassi, C., Kluijt, I., Levy, M.J., Chak, A., Fockens, P., Goggins, M., CAPS Consortium, x, Bruno, M., Canto, M.I., Harinck, F., Hruban, R.H., Offerhaus, G.J.A., Poley, J.W., Kamel, I., Nio, Y., Schulick, R.S., Bassi, C., Kluijt, I., Levy, M.J., Chak, A., Fockens, P., Goggins, M., CAPS Consortium, x, and Bruno, M.
- Published
- 2013
9. International cancer of the pancreas screening (CAPS) consortium summit on the management of patients with increased risk for familial pancreatic cancer
- Author
-
Canto, M.I. (Marcia Irene), Harinck, F. (Femme), Hruban, R.H. (Ralph), Offerhaus, G.J.A. (Johan), Poley, J.-W. (Jan-Werner), Kamel, M.S. (Mohamed), Nio, C.Y. (Yung), Schulick, R. (Richard), Bassi, C. (Claudio), Kluijt, I. (Irma), Levy, M.L. (Michael), Chak, A. (Amitabh), Fockens, P. (Paul), Goggins, M. (Michael), Bruno, M.J. (Marco), Canto, M.I. (Marcia Irene), Harinck, F. (Femme), Hruban, R.H. (Ralph), Offerhaus, G.J.A. (Johan), Poley, J.-W. (Jan-Werner), Kamel, M.S. (Mohamed), Nio, C.Y. (Yung), Schulick, R. (Richard), Bassi, C. (Claudio), Kluijt, I. (Irma), Levy, M.L. (Michael), Chak, A. (Amitabh), Fockens, P. (Paul), Goggins, M. (Michael), and Bruno, M.J. (Marco)
- Abstract
Background Screening individuals at increased risk for pancreatic cancer (PC) detects early, potentially curable, pancreatic neoplasia. Objective To develop consortium statements on screening, surveillance and management of high-risk individuals with an inherited predisposition to PC. Methods A 49-expert multidisciplinary international consortium met to discuss pancreatic screening and vote on statements. Consensus was considered reached if ≥75% agreed or disagreed. Results There was excellent agreement that, to be successful, a screening programme should detect and treat T1N0M0 margin-negative PC and high-grade dysplastic precursor lesions (pancreatic intraepithelial neoplasia and intraductal papillary mucinous neoplasm). It was agreed that the following were candidates for screening: first-degree relatives (FDRs) of patients with PC from a familial PC kindred with at least two affected FDRs; patients with Peutz–Jeghers syndrome; and p16, BRCA2 and hereditary non-polyposis colorectal cancer (HNPCC) mutation carriers with ≥1 affected FDR. Consensus was not reached for the age to initiate screening or stop surveillance. It was agreed that initial screening should include endoscopic ultrasonography (EUS) and/or MRI/magnetic resonance cholangiopancreatography not CT or endoscopic retrograde cholangiopancreatography. There was no consensus on the need for EUS fine-needle aspiration to evaluate cysts. There was disagreement on optimal screening modalities and intervals for follow-up imaging. When surgery is recommended it should be performed at a high-volume centre. There was great disagreement as to which screenin
- Published
- 2013
- Full Text
- View/download PDF
10. International Cancer of the Pancreas Screening (CAPS) Consortium summit on the management of patients with increased risk for familial pancreatic cancer
- Author
-
Cancer, Pathologie, Canto, M.I., Harinck, F., Hruban, R.H., Offerhaus, G.J.A., Poley, J.W., Kamel, I., Nio, Y., Schulick, R.S., Bassi, C., Kluijt, I., Levy, M.J., Chak, A., Fockens, P., Goggins, M., CAPS Consortium, x, Bruno, M., Cancer, Pathologie, Canto, M.I., Harinck, F., Hruban, R.H., Offerhaus, G.J.A., Poley, J.W., Kamel, I., Nio, Y., Schulick, R.S., Bassi, C., Kluijt, I., Levy, M.J., Chak, A., Fockens, P., Goggins, M., CAPS Consortium, x, and Bruno, M.
- Published
- 2013
11. Screening for Early Pancreatic Neoplasia in High-Risk Individuals: A Prospective Controlled Study
- Author
-
Canto, M.I., primary
- Published
- 2006
- Full Text
- View/download PDF
12. Special article Chemoprevention for Barrett's Esophagus Trial. Design and outcome measures.
- Author
-
Heath, E.I., Canto, M.I., Wu, T.-T., Piantadosi, S., Hawk, E., Unalp, A., Gordon, G., and Forastiere, A.A.
- Subjects
- *
ESOPHAGUS diseases , *CHEMOPREVENTION , *NONSTEROIDAL anti-inflammatory agents , *CYCLOOXYGENASE 2 , *CELECOXIB - Abstract
Barrett's esophagus is a premalignant condition in which normal squamous epithelium of the esophagus is replaced by metaplastic columnar epithelium. It is a known risk factor for the development of esophageal adenocarcinoma. With the incidence of esophageal adenocarcinoma rising, it is reasonable to study Barrett's esophagus as a potential target for therapy that may prevent, delay and/or reverse ongoing tumorigenic processes. Epidemiologic and animal studies support the use of nonsteroidal anti-inflammatory drugs (NSAIDs) in the chemoprevention of several cancers, including esophageal cancer. Cyclo-oxygenase-2 (COX-2) inhibitors are a new class of NSAIDs that inhibit prostaglandin synthesis by selectively blocking the COX-2 enzyme. The COX-2 enzyme has been reported to be over-expressed in premalignant and malignant states, including in Barrett's esophagus and esophageal adenocarcinoma. The Chemoprevention for Barrett's Esophagus Trial (CBET) is a phase IIb, multicenter, randomized, double-masked, placebo-controlled study of the selective COX-2 inhibitor, celecoxib, in patients with Barrett's dysplasia. The sample size is 200 patients with high or low grade Barrett's dysplasia. Celecoxib is administered orally, 200 mg twice per day; the dosing schedule for placebo is the same. Randomization is stratified by dysplasia grade and by clinic. Endoscopy with biopsies is performed at specified time intervals according to the highest grade of dysplasia determined at randomization. The primary outcome measure is the change from baseline to 1 year in the proportion of biopsies exhibiting dysplasia. Secondary outcomes include change from baseline in the maximal grade, extent and surface area of dysplasia. Tertiary outcomes will include measurements of various relevant biomarkers. [ABSTRACT FROM AUTHOR]
- Published
- 2003
- Full Text
- View/download PDF
13. Screening for pancreatic neoplasia in high-risk individuals: an EUS-based approach
- Author
-
Canto, M.I., Goggins, M., Yeo, C.J., Griffin, C., Axilbund, J.E., Brune, K., Ali, S.Z., Jagannath, S., Petersen, G.M., Fishman, E.K., Piantadosi, S., Giardiello, F.M., and Hruban, R.H.
- Abstract
Background & Aims: Relatives of patients with pancreatic cancer and persons with certain inherited syndromes are at increased risk for developing pancreatic cancer. We prospectively evaluated the feasibility of screening for pancreatic neoplasia in high-risk individuals. Methods: Individuals from familial pancreatic cancer kindreds and a patient with Peutz-Jeghers syndrome underwent screening endoscopic ultrasound (EUS). If the EUS was abnormal, EUS-guided fine-needle aspiration, endoscopic retrograde cholangiopancreatography (ERCP), and spiral computed tomography (CT) were performed. Patients with abnormalities suggesting neoplasia had surgery. Results: Thirty-eight patients were studied; 31 (mean age, 58 yr; 42% men) from kindreds with >=3 affected with pancreatic cancer; 6 from kindreds with 2 affected relatives, 1 was a patient with Peutz-Jeghers syndrome. None had symptoms referable to the pancreas or suggestive of malignancy. Six pancreatic masses were found by EUS: 1 invasive ductal adenocarcinoma, 1 benign intraductal papillary mucinous neoplasm, 2 serous cystadenomas, and 2 nonneoplastic masses. Hence, the diagnostic yield for detecting clinically significant pancreatic neoplasms was 5.3% (2 of 38). The 1 patient with pancreatic cancer was treated and still is alive and disease-free >5 years after surgery. EUS changes similar to those associated with chronic pancreatitis were found, which were more common in patients with a history of regular alcohol intake (P = 0.02), but also occurred in patients who did not consume alcohol. Screening also led to a new diagnosis and treatment of symptomatic upper-gastrointestinal conditions in 18.4% of patients. Conclusions: EUS-based screening of asymptomatic high-risk individuals can detect prevalent resectable pancreatic neoplasia but false-positive diagnoses also occur.
- Published
- 2004
- Full Text
- View/download PDF
14. Clinical usefulness of 3% hydrogen peroxide in acute upper GI bleeding: a pilot study
- Author
-
Kalloo, A.N., Canto, M.I., Wadwa, K.S., Smith, C.L., Gislason, G.T., Okolo, P.I., and Pasricha, P.J.
- Abstract
Background: A major problem in the endoscopic management of acute upper gastrointestinal (GI) bleeding is the presence of blood and clots overlying the bleeding source, preventing visualization of the lesion. A simple alternative is to alter the characteristics of blood such that it not only becomes easier to remove but also becomes translucent. We report the results of a pilot study on the use of hydrogen peroxide in patients with acute upper GI bleeding. Methods: Patients with acute upper GI bleeding were studied if the presence of blood or clots obscured the site of bleeding. The potential site of bleeding was initially sprayed with 200 mL water and then with 200 mL 3% hydrogen peroxide mixed with simethicone. Results: In 6 patients with acute upper GI bleeding, hydrogen peroxide spray resulted in good to excellent visualization of the bleeding source. Hemostasis occurred in 2 patients who were actively bleeding. There were no adverse effects or complications. Conclusions: Hydrogen peroxide significantly enhanced clot dissolution and endoscopic visualization in patients with acute upper GI bleeding.
- Published
- 1999
- Full Text
- View/download PDF
15. Endoscopic cryotherapy: experimental results and first clinical use
- Author
-
Pasricha, P.J., Hill, S., Wadwa, K.S., Gislason, G.T., Okolo, P.I., Magee, C.A., Canto, M.I., Kuo, W.H., Baust, J.G., and Kalloo, A.N.
- Abstract
Background: Cryotherapy or the application of extreme cold has many potential applications in gastroenterology including tissue destruction and hemostasis but until now its development has been prevented by the lack of a delivery device suitable for use through the endoscope. We report here our experience with prototype devices using both liquid nitrogen driven by a cryosurgical system and cryogenic refrigerants (nitrous oxide and carbon dioxide) at or near ambient temperature. Methods: Cryotherapy was applied to the distal esophageal mucosa of dogs via a flexible catheter passed through an upper endoscope. In other dogs, cryotherapy was used for hemostasis in a bleeding ulcer model. The procedure was also used for palliation in a 58-year-old man with unresectable adenocarcinoma of the stomach with pyloric channel obstruction. Results: Freezing of the superficial mucosa was nearly instantaneous. All dogs survived the procedure and appeared to thrive. Histologic evaluation revealed significant necrosis of the superficial epithelial layer accompanied by a fibrinocellular infiltrate on the surface. These markers of acute injury subside by the fourth to sixth day and are replaced by regenerating epithelium, a process that is virtually complete by day 10. In the hemostasis experiments, bleeding ceased immediately after cryospraying of the lesions but resumed on thawing in most cases. Application of cryotherapy in the patient resulted in reduction of the pyloric mass with no immediately apparent adverse effects. Conclusions: These data, although preliminary, demonstrate the feasibility of endoscopic cryotherapy using a simple hand-held device. This device has broad potential for use in gastroenterology including ablation of superficial epithelium, debulking of large tumors and hemostasis.
- Published
- 1999
- Full Text
- View/download PDF
16. Clinical implications of endoluminal ultrasonography using through-the-scope catheter probes
- Author
-
Chak, A., Soweid, A., Hoffman, B., Stevens, P., Hawes, R.H., Lightdale, C.J., Cooper, G.S., Canto, M.I., and Sivak, M.V.
- Abstract
Background: Ultrasound catheter probe-assisted endosonography is a relatively new technique. The aim of this prospective multicenter study was to determine its potential clinical impact by assessing changes in diagnostic and therapeutic management affected by catheter probes compared with ultrasound endoscopes. Methods: Endosonographers at three centers selected theoretic diagnostic and therapeutic plans that would be followed if neither catheter probes nor ultrasound endoscopes were available. Patients with suitable lesions underwent endosonography with catheter probes followed by an ultrasound endoscope. Diagnostic and therapeutic plans were noted after each examination. Results: Sixty-six patients, of whom 15 had a stenotic esophageal cancer, 39 had a mucosal or submucosal lesion, and 12 had a stricture of the pancreaticobiliary system or the gastrointestinal tract, were enrolled. If neither form of endosonography were available, invasive or surgical diagnostic procedures would have been performed on 23 (35%) patients and surgical therapy would have been planned in 31 (47%) patients. Catheter probe-assisted ultrasonography and endoscopic ultrasonography led to a less invasive diagnostic plan in 11 (16%) and 12 (18%) patients and a less invasive therapeutic plan in 10 (15%) and 14 (21%) patients, respectively (p > 0.1 for differences). Conclusions: Catheter probe-assisted endosonography has a modest effect on diagnostic and therapeutic management, comparable with endoscopic ultrasonography in the same patients. The vast majority of effected changes are toward less invasive management. (Gastrointest Endosc 1998;48:485-90.)
- Published
- 1998
- Full Text
- View/download PDF
17. Diagnostic and therapeutic impact of push enteroscopy: analysis of factors associated with positive findings
- Author
-
Chak, A., Koehler, M.K., Sundaram, S.N., Cooper, G.S., Canto, M.I., and Sivak, M.V.
- Abstract
Background: Push enteroscopy is indicated in patients with suspected small bowel gastrointestinal bleeding or small bowel mucosal disease. Our aim was to determine the diagnostic yield of enteroscopy, identify clinical predictors associated with findings, and measure frequency of management changes made on the basis of results. Methods: Endoscopy reports, office charts, and hospital charts were reviewed for 164 patients who had enteroscopy performed, primarily with a video enteroscope, during a period of 2 years. Data extraction included details of comorbid illnesses, associated risk factors, and previous endoscopies. Results: Indications for enteroscopy were suspected occult bleeding in 65, overt bleeding in 64, diarrhea in 20, and suspected mucosal disease in 15 patients. Diagnostic lesions, identified in 92 patients (56%), included 57 jejunal lesions (35%). In patients with overt bleeding, upper tract lesions were present more commonly in patients receiving nonsteroidal medication (54% versus 27%, p < 0.05). Jejunal vascular ectasia occurred more frequently in patients with documented vascular ectasias elsewhere in the gastrointestinal tract (34% versus 15%, p < 0.01). Missed lesions on previous upper endoscopy included large hiatal hernias with erosions in 10, peptic ulcers in 10, and vascular ectasias in 9 patients. Therapeutic interventions, made in 67 of 92 patients (73%) with diagnostic lesions, included small bowel resection in 12 (8%), endoscopic therapy in 21 (14%), and changes in medical regimen in 34 patients (22%). Conclusions: Push enteroscopy with video enteroscopes has a moderate diagnostic yield. Positive findings frequently lead to therapy changes. Large hiatal hernias remain an underrecognized etiology of anemia. Repeat upper endoscopy should be considered before enteroscopy in patients taking nonsteroidals who develop overt bleeding. (Gastrointest Endosc 1998;47:18-22.)
- Published
- 1998
- Full Text
- View/download PDF
18. Enteroscopy for the initial evaluation of iron deficiency
- Author
-
Chak, A., Cooper, G.S., Canto, M.I., Pollack, B.J., and Sivak, M.V.
- Abstract
Background: Occult gastrointestinal blood loss is generally investigated with colonoscopy and esophagogastroduodenoscopy in patients with iron-deficiency anemia. The aim of this study was to prospectively measure the additional diagnostic yield of examining the jejunum at the time of upper endoscopy in patients with iron-deficiency anemia. Methods: Asymptomatic patients with newly diagnosed iron-deficiency anemia who had no identifiable source of blood loss at colonoscopy underwent standard esophagogastroduodenoscopy with the Olympus SIF100L enteroscope followed by overtube-assisted enteroscopy. Upper tract and jejunal sources of blood loss were noted. Biopsy samples from the small bowel were taken when a bleeding lesion was not identified. Results: Thirty-one consecutive patients (13 men, mean age 71) with no gastrointestinal symptomatology were studied. Eleven patients (35%) had a bleeding source that required only esophagogastroduodenoscopy for identification; 8 patients (26%) had a source only in the jejunum; 2 patients (6%) (one with sprue) had a source in upper tract as well as jejunum. The enteroscopy was rated as causing minimal or mild discomfort in 25 of 31 patients (81%). Using Medicare reimbursement figures, a strategy of performing esophagogastroduodenoscopy first would have cost $656 per patient, whereas the strategy of performing esophagogastroduodenoscopy with enteroscopy as the initial test in all patients costs $467 per patient. Conclusions : Performance of push enteroscopy along with esophagogastroduodenoscopy increases the diagnostic yield from 41% to 67% when evaluating the upper gastrointestinal tract of asymptomatic patients with iron-deficiency anemia and, because of a lower cost, should be the preferred initial diagnostic test. (Gastrointest Endosc 1998:47:144-48)
- Published
- 1998
- Full Text
- View/download PDF
19. Endosonographic differentiation of benign and malignant stromal cell tumors
- Author
-
Chak, A., Canto, M.I., Rosch, T., Dittler, H.J., Hawes, R.H., Tio, T., Lightdale, C.J., Boyce, H., Scheiman, J., Carpenter, S.L., Dam, J.V., Kochman, M.L., and Sivak, M.V.
- Abstract
Background: Endosonography (EUS) is a valuable technique for diagnosing gastrointestinal stromal cell tumors. However, EUS features that are predictive of malignancy in these tumors have not been defined. Methods: Videotapes and photographs of EUS examinations performed prior to surgical resection of 35 stromal cell tumors (9 malignant) were blindly reviewed by a single examiner. EUS features associated with malignancy were determined. Interobserver agreement in interpreting these features was then measured among a panel of five expert endosonographers who judged EUS videotapes of 35 resected stromal cell tumors (10 malignant). Results: Stepwise logistic regression analysis demonstrated that tumor size (diameter > 4 cm), irregular extraluminal border, echogenic foci, and cystic spaces were independently associated with malignancy in stromal cell tumors (p < 0.05). Interobserver agreement for irregular extraluminal border, echogenic foci, and cystic spaces, as measured by mean kappa statistic, was 0.43, 0.39, and 0.28, respectively. For the five experts, the sensitivity for detecting malignancy ranged between 80% to 100% when at least two of the three features were judged to be present. The likelihood of finding malignancy ranged between 0% to 11% for the experts when all three features were judged absent. Conclusions: Tumor size and certain EUS features are useful for predicting malignancy in stromal cell tumors. Absence of these features indicates benign disease. Agreement among experts in interpreting these EUS features is fair to moderate. (Gastrointest Endosc 1997;45:468-73.)
- Published
- 1997
- Full Text
- View/download PDF
20. Barrett's esophagus and early esophageal cancer
- Author
-
Canto, M.I.
- Published
- 2002
- Full Text
- View/download PDF
21. Optical coherence microscopy in gastrointestinal tissues.
- Author
-
Izatt, J.A., Hsing-Wen Wang, Kulkarni, M., Canto, M.I., and Sivak, M.V.
- Published
- 1996
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.